[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2005524670A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524670A5
JP2005524670A5 JP2003574168A JP2003574168A JP2005524670A5 JP 2005524670 A5 JP2005524670 A5 JP 2005524670A5 JP 2003574168 A JP2003574168 A JP 2003574168A JP 2003574168 A JP2003574168 A JP 2003574168A JP 2005524670 A5 JP2005524670 A5 JP 2005524670A5
Authority
JP
Japan
Prior art keywords
hours
carbidopa
time
water contact
rapid release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003574168A
Other languages
Japanese (ja)
Other versions
JP2005524670A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/006591 external-priority patent/WO2003075893A1/en
Publication of JP2005524670A publication Critical patent/JP2005524670A/en
Publication of JP2005524670A5 publication Critical patent/JP2005524670A5/ja
Pending legal-status Critical Current

Links

Claims (1)

前記３時間以上の時間が、前記投与形態と水が接触する１〜２時間後に始まり、当該時間は、カルビドパの初期の一層急速な放出より前である請求項２６に記載の医薬投与形態。 Wherein three or more hours, the dosage starts to form a 1-2 hours after water contact, the time, the pharmaceutical dosage form of claim 26 Ru Ah before even more rapid release early carbidopa.
JP2003574168A 2002-03-04 2003-03-03 Controlled release dosage form Pending JP2005524670A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36182102P 2002-03-04 2002-03-04
US29161902A 2002-11-12 2002-11-12
PCT/US2003/006591 WO2003075893A1 (en) 2002-03-04 2003-03-03 Controlled release dosage forms

Publications (2)

Publication Number Publication Date
JP2005524670A JP2005524670A (en) 2005-08-18
JP2005524670A5 true JP2005524670A5 (en) 2006-04-13

Family

ID=27807664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003574168A Pending JP2005524670A (en) 2002-03-04 2003-03-03 Controlled release dosage form

Country Status (13)

Country Link
EP (1) EP1492508A4 (en)
JP (1) JP2005524670A (en)
KR (1) KR20100049695A (en)
CN (1) CN1649569B (en)
AU (2) AU2003217909C1 (en)
BR (1) BR0308305A (en)
CA (1) CA2477701A1 (en)
EA (1) EA005866B1 (en)
IL (1) IL163887A0 (en)
MX (1) MXPA04008536A (en)
NO (1) NO20044188L (en)
NZ (1) NZ535083A (en)
WO (1) WO2003075893A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
EP1524978A2 (en) * 2002-07-19 2005-04-27 Ranbaxy Laboratories, Ltd. Taste masked sumatriptan tablets and processes for their preparation
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
NZ540106A (en) * 2002-11-12 2008-03-28 Teva Pharma Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
EP1698448B1 (en) * 2003-11-14 2017-01-18 Sanwa Kagaku Kenkyusho Co., Ltd. Method of manufacturing nucleated molding
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US7579333B2 (en) * 2004-02-19 2009-08-25 Teva Pharmaceutical Industries Ltd. Therapy using a combination of raloxifene and alendronate
KR100701409B1 (en) 2004-11-26 2007-03-30 한국유나이티드제약 주식회사 Pharmaceutical formulations containing sumatriptan succinate
MX340249B (en) 2008-08-15 2016-07-01 Depomed Inc Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders.
CN103948556A (en) * 2014-04-08 2014-07-30 闻晓光 Novel controlled release tablet
JP6878417B2 (en) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド Dosage forms and their use
CN110604724A (en) * 2019-10-22 2019-12-24 恒诚制药集团淮南有限公司 Enteric mesalazine sustained-release tablet and preparation method thereof
WO2024081456A1 (en) * 2022-10-13 2024-04-18 Clarke Mosquito Control Products, Inc. Insecticidal tablet compositions
JP2024083720A (en) * 2022-12-12 2024-06-24 パナソニックＩｐマネジメント株式会社 Sustained-release solid medical agent for water treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
JPS61243016A (en) * 1985-04-19 1986-10-29 Katsumi Takada Tablet having columnar part containing active constituent
GB8514666D0 (en) * 1985-06-11 1985-07-10 Coopers Animal Health Agent delivery systems
JPS6253918A (en) * 1985-09-02 1987-03-09 Katsumi Takada Tablet containing embedded columnar part containing active component
DE4431653C2 (en) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Coated tablet for the controlled release of active substances, a process for their preparation and their use
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
JP3962108B2 (en) * 1995-04-03 2007-08-22 中外製薬株式会社 Sucralfate-containing pharmaceutical composition
CA2184316A1 (en) * 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
SI0931543T1 (en) * 1997-12-19 2002-10-31 Merck Patent Gmbh Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria
ATE260105T1 (en) * 1997-12-22 2004-03-15 Schering Corp PREPARATION CONTAINING A MOLECULAR DISPERSION WITH INCREASED BIOAVAILABILITY
JP4748839B2 (en) * 1999-03-25 2011-08-17 大塚製薬株式会社 Cilostazol preparation
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
ATE417609T1 (en) * 2000-06-28 2009-01-15 Palmetto Pharmaceuticals Llc COMPOSITIONS OF ARGININE WITH CONTROLLED RELEASE
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it

Similar Documents

Publication Publication Date Title
JP2005524670A5 (en)
JP2006503588A5 (en)
JP2006524283A5 (en)
JP2004210767A5 (en)
JP2003503454A5 (en)
JP2005519316A5 (en)
JP2006507281A5 (en)
JP2008501714A5 (en)
DE502005009109D1 (en) SOLID, ORAL APPLICABLE PHARMACEUTICAL FORMS OF PREPARATION CONTAINING RIVAROXABAN WITH MODIFIED RELEASE
JP2010507682A5 (en)
JP2006506499A5 (en)
JP2004534810A5 (en)
IT1318376B1 (en) ORAL SOLID FORMS WITH CONTROLLED RELEASE CONTAINING MESALAZINE AS AN ACTIVE PRINCIPLE.
JP2006525972A5 (en)
JP2008519810A5 (en)
RU2002107079A (en) Sedative
JP2008517002A5 (en)
JP2007508806A5 (en)
JP2006522596A5 (en)
JP2004224775A5 (en)
RU2006124991A (en) HEEL
JP2005531640A5 (en)
JP2005506372A5 (en)
TH81079EX (en) toilet
TH81078EX (en) toilet